stoxline Quote Chart Rank Option Currency Glossary
  
G1 Therapeutics, Inc. (GTHX)
4.11  -0.06 (-1.44%)    04-19 16:00
Open: 4.13
High: 4.305
Volume: 732,115
  
Pre. Close: 4.17
Low: 3.97
Market Cap: 215(M)
Technical analysis
2024-04-19 5:09:52 PM
Short term     
Mid term     
Targets 6-month :  5.71 1-year :  6.67
Resists First :  4.89 Second :  5.71
Pivot price 4.51
Supports First :  3.68 Second :  2.93
MAs MA(5) :  4.19 MA(20) :  4.44
MA(100) :  3.43 MA(250) :  2.61
MACD MACD :  0.1 Signal :  0.2
%K %D K(14,3) :  22 D(3) :  23.1
RSI RSI(14): 48.4
52-week High :  5 Low :  1.08
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ GTHX ] has closed above bottom band by 9.7%. Bollinger Bands are 44.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.31 - 4.34 4.34 - 4.36
Low: 3.91 - 3.93 3.93 - 3.96
Close: 4.06 - 4.11 4.11 - 4.16
Company Description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Headline News

Fri, 19 Apr 2024
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit - Yahoo Finance

Thu, 18 Apr 2024
Raymond James & Associates Trims Stock Position in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat

Wed, 17 Apr 2024
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 - GlobeNewswire

Tue, 16 Apr 2024
RPRX: 3 Biotech Stocks to Watch for Lucrative Gains - StockNews.com

Sun, 07 Apr 2024
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) market cap touched US$250m last week, benefiting both retail investors who own 59% as well as institutions - Simply Wall St

Fri, 22 Mar 2024
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape (NASDAQ:GTHX) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 52 (M)
Shares Float 44 (M)
Held by Insiders 11.6 (%)
Held by Institutions 30.1 (%)
Shares Short 2,760 (K)
Shares Short P.Month 2,910 (K)
Stock Financials
EPS -0.94
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.68
Profit Margin -58.2 %
Operating Margin -60.1 %
Return on Assets (ttm) -16 %
Return on Equity (ttm) -92.2 %
Qtrly Rev. Growth 45 %
Gross Profit (p.s.) 0
Sales Per Share 1.58
EBITDA (p.s.) -0.75
Qtrly Earnings Growth 0 %
Operating Cash Flow -38 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -4.42
PEG Ratio 0
Price to Book value 6.04
Price to Sales 2.6
Price to Cash Flow -5.6
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android